fda compounding semaglutide enforcement november 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Congress Introduces SAFE Drugs Act

Repeat at 6 months to assess initial response

Another red flag is unusually low pricing, which may indicate the use of cheap, substandard, or even fake ingredients

This effort included issuing a wave of warning letters to telehealth providers and companies promoting compounded GLP-1 products

This comprehensive approach ensures that patients achieve their weight loss goals in a fashion that is both healthy and sustainable

Their beginning marks a woman's entry into perimenopause

Early studies suggest retatrutide may lead to more weight loss than current options, with people losing around 24% of their body weight compared to about 21% with Zepbound and 15% with Wegovy